Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof

Abstract

In order to provide a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to neutralize SARS-CoV-2, an antigen-binding fragment thereof, and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, the present invention provides: a human-derived monoclonal antibody against SARS-CoV-2, the antibody binding to the S protein of SARS-CoV-2 to neutralize viral activity of the S protein including an immune escape mutation; an antigen-binding fragment thereof; nucleic acids encoding the antibody and the antigen-binding fragment thereof; and a pharmaceutical composition for treating or preventing a SARS-CoV-2 coronavirus infectious disease, the pharmaceutical composition containing the antibody or the antigen-binding fragment thereof.

Dependencies are inferred from the claim text.